Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Session Type:

Availability:

Participation Type:

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 sessions: 1 to 25 of 25
Scripps CHAVI-ID Satellite Session: Structure and Antigenicity of Soluble, Cleaved (SOSIP) HIV-1 gp140 Trimers
Session Introduction
Dennis Burton
The Scripps Research Institute, La Jolla, California USA
John Moore
Weill Medical College of Cornell University, New York, NY USA
Antigenic structure of BG505 SOSIP.664 gp140 trimers
Rogier Sanders
Academic Medical Center, Amsterdam, Holland
The importance of cleavage for gp140 trimers to adopt native-like conformations; and the immunogenicity of BG505 SOSIP.664 gp140 trimers
John Moore
Weill Medical College of Cornell University, New York, NY USA
Cryo-EM structure of the BG505 SOSIP.664 gp140 trimer
Andrew Ward
The Scripps Research Institute, La Jolla, California USA
X-ray structure of the BG505 SOSIP.664 gp140 trimer
Ian Wilson
The Scripps Research Institute, La Jolla, CA, United States of America
Panel Discussion and Questions
Dennis Burton
The Scripps Research Institute, La Jolla, California USA
Jean-Philippe Julien
The Scripps Research Institute, La Jolla, California USA
Per Johan Klasse
Weill Medical College of Cornell University, New York, NY USA
John Moore
Weill Medical College of Cornell University, New York, NY USA
Rogier Sanders
Academic Medical Center, Amsterdam, Holland
Andrew Ward
The Scripps Research Institute, La Jolla, California USA
Ian Wilson
The Scripps Research Institute, La Jolla, CA, United States of America
from AIDS Vaccine 2013 on 7 October 2013 12:00 PM-3:00 PM
Opening Session
Welcome Remarks
Christian Brander
IrsiCaixa Foundation, HIVACAT, ICREA, Barcelona, Spain, Barcelona, Spain
Welcome Remarks
Bonaventura Clotet
IrsiCaixa Foundation, HIVACAT, Barcelona, Spain
Welcome Remarks
José M. Gatell
Hospital Clínic-IDIBAPS, University of Barcelona, HIVACAT, Spain, Barcelona, Spain
Remarks
Enric Banda
Director of the Area of Science, Research and the Environment, ”la Caixa” Foundation, Barcelona, Spain
Remarks
Eduard Valenti
Esteve, Spain
Remarks
Boi Ruiz i Garcia
Minister of Health, Government of Catalonia, Barcelona, Spain
Opening Remarks from the Vaccine Enterprise
William Snow
Global HIV Vaccine Enterprise, New York, NY, United States of America
Partnership Towards A Tough Target: Communities are an Essential Ingredient, Not a Cherry on Top
Ntando Yola
NACOSA, Cape Town, South Africa
HIV Vaccines in the Context of Vaccine Development in General
Stanley A Plotkin
University of Pennsylvania, Doylestown, PA, United States of America
Insights from HIV Vaccine Efficacy Trials: What We Are Learning from HVTN 505
Magdalena Sobieszczyk
Columbia University, New York, NY, United States of America
Toward Ending the HIV/AIDS Pandemic: Synergy between Vaccine and Non-Vaccine Interventions
Anthony Fauci
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States of America
from AIDS Vaccine 2013 on 7 October 2013 4:00 PM-6:00 PM
Plenary 01: HIV Vaccine Strategies
Innate Immune Control in HIV and Implications for Vaccine Development
Nicole Bernard
McGill University, Montreal, Canada
Vaccine Induction of T cell Immunity to HIV-1
Andrew McMichael
University of Oxford, Oxford, United Kingdom (Great Britain)
Pathways of Affinity Maturation of HIV-1 Broadly Neutralizing Antibodies
Barton Haynes
Duke Human Vaccine Institute, Durham, NC, United States of America
from AIDS Vaccine 2013 on 8 October 2013 8:30 AM-10:00 AM
Oral Abstract Session 01: T Cell Immunology
Effective CD8+ T cell responses restrict SIV replication to Follicular Helper T Cells.
Yoshinori Fukazawa
Vaccine and Gene Therapy Institute, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, United States of America
The Breadth of Expandable Central Memory CD8 T cells inversely correlates with Residual Viral loads in HIV Elite Controllers
Zaza Ndhlovu
University of KwaZulu Natal, Nelson Mandela School of Medicine, HIV Pathogenesis Programme, Durban, South Africa
PD-1 expression on HIV-1 specific CD8+ T cells is shaped by epitope specificity, TcR clonotype usage and driven by antigen load
Henrik N. Kløverpris
KwaZulu-Natal Research Instititute for Tuberculosis and HIV, K-RITH, University of KwaZulu-Natal, Nelson R. Mandela School of Medicine, Durban, South Africa
Immunotherapeutic interventions to restore HIV-1-specific CD4 T cell help to NK cells
Filippos Porichis
Ragon Institue of MGH, MIT and Harvard, Cambridge, MA, United States of America
Integrative analysis of responses to Dendritic-Cell vaccination identifies signatures correlated with control of HIV replication: the DALIA trial
Rodolphe THIEBAUT
INSERM U897, Biostatistics / SISTeM, Bordeaux, France
Effective Antiviral CD8+ T cells responses are rare in HIV-positive Step & Phambili Study participants but are targeted to Low Entropy Viral Epitopes
Gemma Hancock
University of Oxford, oxford, United Kingdom (Great Britain)
from AIDS Vaccine 2013 on 8 October 2013 10:30 AM-12:00 PM
Oral Abstract Session 02: Adjuvants
Engineering an HIV Envelope Protein to Activate Germline B Cell Receptors of Broadly Neutralizing VRC01-Class Antibodies
Andrew McGuire
Seattle Biomed, Seattle, WA, United States of America
Focusing Antibody Responses to Specific Protein Surfaces Through Site-Selective Glycan Addition
Torben Schiffner
University of Oxford, The Sir William Dunn School of Pathology, Oxford, United Kingdom (Great Britain)
Comparative Antigenicity and Immunogenicity of Indian and South African HIV-1 Subtype C Native and CD4 Liganded Envelope Glycoproteins
Maria A Papathanasopoulos
University of the Witwatersrand Medical School, Molecular Medicine and Haematology, Johannesburg, South Africa
Immunogenicity of a CD207-Targeted anti-Gag Vaccine and TLR Ligand-Dependent Enhancement
Frederic Martinon
CEA, Division of Immuno-Virology, Fontenay aux Roses, France
Impact of TLR9 Stimulation on HIV-1 Env-specific Immune Responses Elicited in Non-human primates
Paola Andrea Martinez Murillo
Karolinska Institutet, Microbiology, Tumor and Cell biology, Stockholm, Sweden
Lipid Components in MPER-based Immunization Regimens are Critical for Inducing Broadly Neutralizing Antibody Responses in 2F5 and 4E10 Knockin Mice
Laurent Verkoczy
Duke Human Vaccine Institute, Durham, NC, United States of America
from AIDS Vaccine 2013 on 8 October 2013 10:30 AM-12:00 PM
Oral Abstract Session 03: Clinical Trials
The HIVconsv Vaccines Induce Polyfunctional and Highly Proliferative T cells that Control in vitro HIV replication: HIV-CORE002 Phase-I clinical trial
Beatrice O Ondondo
University of Oxford, Nuffield department of Medicine, Oxford, United Kingdom (Great Britain)
Phase I clinical trials of DNA-protein vaccine (CombiHIVvac) containing artificial multi-clade immunogens
Larisa Karpenko
State Research Center of Virology and Biotechnology «Vector», recombinant vaccine, Koltsovo, Novosibirsk, Russian Federation
Comparative Analysis of Binding Antibody Responses elicited by a Cross-Section of Human HIV-1 Vaccine Clinical Trials
Shelly J. Krebs
U.S. Military HIV Research Program, Walter Reed Army Institute of Research; Henry M. Jackson Foundation for the Advancement of Military Medicine, Silver Spring, MD, United States of America
Antibody Repertoire Induced by the Multiclade (Env A,B,C) HIV-1 DNA Prime, rAd5 Boost VRC Vaccine
Wilton B Williams
Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, United States of America
A Phase I Clinical Trial of an HIV-1(CN54), Clade C, Trimeric Envelope Vaccine Delivered by Parenteral, Nasal and Vaginal Routes of Immunisation
Catherine A Cosgrove
St George's, University of London, Infection and Immunity, London, United Kingdom (Great Britain)
HIV-1 Fusion Protein (F4/AS01) and Adenovirus-35 Gag-RT-Int-Nef Induce Potent and Durable T-cell and Antibody Responses in Healthy African Adults
Juliet Mpendo
Uganda Virus Research Institute, UVRI-IAVI HIV Vaccine Program, Entebbe, Uganda
from AIDS Vaccine 2013 on 8 October 2013 10:30 AM-12:00 PM
Oral Abstract Session 04: Animal Models
PET/CT Imaging of Simian Immunodeficiency Virus Reveals the Dynamics of Viral Replication in vivo.
Francois Villinger
Emory University, Department of Pathology & Laboratory Medicine and Yerkes National Primate Research Center, Pathology, Atlanta, GA, United States of America
Non-human primate model to study the role of serum and vaginal IgA in acquisition of infection
Megan Wise
University of Pennsylvania, Doylestown, PA, United States of America
Vaccine Induced Epitope Specific Antibodies to the SIV Envelope are Distinct from Those Induced to the HIV-1 Envelope
Xiaoying Shen
Duke University, Human Vaccine Institute, Durham, NC, United States of America
Co-administration of Rapamycin with a DNA/MVA SIV Vaccine Improves Memory CD8 T Cell Response and Enhances Control of SIV251 Infection
Rama Amara
Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA
Protection of Cynomolgus Macaques from pathogenic SIV following vaccination with Varicella-Zoster virus based vaccines.
Kelly S MacDonald
Mt. Sinai Hospital, Department of Microbiology, University of Toronto, Department of Medicine, Microbiology, Toronto, Canada
Therapeutic Efficacy of Potent Neutralizing HIV-1-Specific Monoclonal Antibodies in SHIV-Infected Rhesus Monkeys
Dan Barouch
Beth Israel Deaconess Medical Center, Center for Virology and Vaccine Research, Boston, MA, United States of America
from AIDS Vaccine 2013 on 8 October 2013 1:00 PM-2:30 PM
Oral Abstract Session 05: B Cell Immunology
Structural Basis for HIV-1 gp120 Recognition by a Germ-line Version of a Broadly Neutralizing Antibody
Louise Scharf
California Institute of Technology, Biology, Pasadena, CA, United States of America
Structural Characterization of Potent, Longitudinally-Defined HIV-1 V1/V2-Directed Antibodies
Chaim A. Schramm
Columbia University Medical Center, New York, NY, United States of America
Interplay between Broadly Cross-Neutralizing V2 Monoclonal Antibodies and Autologous Viral Evolution
Jinal N. Bhiman
National Institute for Communicable Diseases of the National Health Laboratory Service and University of the Witwatersrand, Centre for HIV and STIs, Johannesburg, South Africa
A diverse antibody response to the gp120 N332 glycan epitope in an HIV-infected donor
Katie J Doores
King's College London and The Scripps Research Institute, Department of Infectious Diseases, London, United Kingdom (Great Britain)
Characterizing the Functional Autoreactivity and Polyspecificity of the MPER-specific bNAb 4E10 and an Ensemble of Its Germline-encoded Precursors
Roland Strong
Fred Hutchinson Cancer Research Center, Seattle, WA
HIV-1 gp120 Vaccination Elicits a Robust and Durable Anti-V1/V2 IgG Response and yet no HIV-1 Env-specific IgA Response in HIV-exposed Infants
Genevieve G. Fouda
Duke University Medical Center, Durham, NC, United States of America
from AIDS Vaccine 2013 on 8 October 2013 1:00 PM-2:30 PM
Oral Abstract Session 06: Vaccine Concepts
Identifying the minimal mutations in VRC01 required for neutralization potency and breadth to inform vaccine design
Joseph G Jardine
The Scripps Research Institute, IAVI, CHAVI-ID, University of Washington, La Jolla, CA, United States of America
Structural Organization and CD4-induced Reorganization in Soluble HIV-1 Trimers
Kelly K. Lee
University of Washington, Medicinal Chemistry, Seattle, WA, United States of America
Cell-Surface Display and Panning of HIV-1 Derived Envelope Proteins
Veronika Schmid
University of Regensburg, Medical Microbiology and Hygiene, Regensburg, Germany
DNA-MVA Prime-Boost Vaccine Eliciting T-Cell Specificities Associated with HIV-1 Control is Highly Immunogenic in Mice and Breaks CTL Immunodominance.
Beatriz Mothe
IrsiCaixa AIDS Research Institute - HIVACAT, Badalona, Spain
Detection of early CTL escape in Gag and Nef using population-level approaches
Zabrina L. Brumme
Simon Fraser University, Faculty of Health Sciences, Burnaby, Canada
Neutralizing and Non-neutralizing Antibody Binding to Cleaved, SOSIP-stabilized and Uncleaved Soluble HIV-1 Env Trimers, Protomers, and gp120
Per Johan Klasse
Weill Medical College of Cornell University, New York, NY USA
from AIDS Vaccine 2013 on 8 October 2013 1:00 PM-2:30 PM
Symposium 01: Innate Immunity
Antiviral Activity of NK Cells in HIV-1 Infection
Marcus Altfeld
Heinrich-Pette-Institut, Hamburg, United States of America
Adjuvants Modify Antibody Effector Function
Alison Mahan
Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, United States of America
Systems Analysis of Innate Immune Responses Triggered by Viral Vector-Based HIV Vaccine Candidates
Daniel Zak
Seattle Biomed, Seattle, WA, United States of America
Systems Vaccinology: Enabling Rational Vaccine Design with Systems Biology
Bali Pulendran
Emory University, Atlanta, GA, United States of America
from AIDS Vaccine 2013 on 8 October 2013 3:00 PM-4:20 PM
Symposium 02: Linking T & B Cell Responses
Memory CD8 T Cells: Issues of Quantity, Quality, and Location
David Masopust
University of Minnesota, Minneapolis, MN, United States of America
Impaired B Cell Help During HIV Infection
Elias Haddad
Vaccine and Gene therapy Institute of Florida, Port St. Lucie, FL, United States of America
Role of Tfh in HIV infection
Giuseppe Pantaleo
Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland
SIAE Inhibition and Enhanced Somatic Hypermutation Against gp140
Shiv Pillai
Massachusetts General Hospital, Charlestown, MA, United States of America
from AIDS Vaccine 2013 on 8 October 2013 3:00 PM-4:20 PM
Symposium 03: NHP Vaccines & Correlates of Immune Protection
Can AIDS Virus-Specific Classical CD8+ T Cells Control Virus Replication?
David Watkins
University of Miami, Miami, FL, United States of America
Pre-Clinical Development of Cytomegalovirus Vectors
Louis Picker
Oregon Health & Science University, Beaverton, OR, United States of America
Vaccine Responses to Four Different gp140 Trimers
Robin Shattock
Imperial College London, London, United Kingdom (Great Britain)
Impressive Vaccine Protection Against SIVmac239 by Recombinant Gamma-2 Herpesvirus
Ronald Desrosiers
New England Primate Research Center, Harvard Medical School, Southborough, MA, United States of America
from AIDS Vaccine 2013 on 8 October 2013 3:00 PM-4:40 PM
Plenary 02: Protection from Infection & Disease Progression
Genital Immunology and HIV Susceptibility
Rupert Kaul
University of Toronto, Ontario, Canada
Immunodeficiency virus and the MHC: Past, Present and Future
Philip Goulder
University of Oxford, Oxford, United States of America
The Role of HIV-1 Viral Evolution in Shaping Broadly Neutralizing Antibodies
Penelope Moore
National institute for Communicable Diseases, Johannesburg, South Africa
from AIDS Vaccine 2013 on 9 October 2013 8:30 AM-10:00 AM
Oral Abstract Session 07: HIV Transmission
Siglec-1 expressed on activated monocytes captures and transfers HIV-1 through recognition of sialyllactose exposed on viral membrane gangliosides
Maria Pino
AIDS Research Insittute Irsicaixa, Barcelona, Spain
Role of Integrin a4ß7 in HIV Transmission and Pathogenesis
Simone Irene Richardson
Centre for HIV and STIs, National Institute for Communicable Diseases, HIV Virology, Johannesburg, South Africa
Profound Alterations in Cholesterol Metabolism Restrict HIV-1 Trans Infection of CD4 T Cells in Viremic Controllers
Giovanna Rappocciolo
University of Pittsburgh, Infectious Disease and Microbiology, Pittsburgh, PA, United States of America
Highly Potent Broadly Neutralizing Antibodies Lack Potential to Inhibit HIV-1 Cell-to-Cell Transmission
Lucia Reh
Institute of Medical Virology, University of Zurich, Zurich, Switzerland
Highly Pathogenic Adapted HIV-1 Strains Limit Immune Responses and Dictates Rapid Disease Progression in early infection
Julia G Prado
AIDS Research Insittute Irsicaixa, Barcelona, Spain
Genetic selection bias at the heterosexual HIV-1 transmission bottleneck
Jonathan Carlson
Microsoft Research, Los Angeles, CA, United States of America
from AIDS Vaccine 2013 on 9 October 2013 10:30 AM-12:00 PM
Oral Abstract Session 08: Innate & Mucosal Immunity
Gut-homing of plasmacytoid dendritic cells persists in the absence of HIV/SIV replication and contributes to residual chronic immune activation
R. Keith Reeves
NEPRC, Harvard Medical School, Southborough, MA, United States of America
HIV-1 Infection Induces Potent Type I IFN Signatures in Conventional Dendritic Cells from HIV-1- Elite Controllers
Enrique Martin-Gayo
Ragon Institute of MGH, MIT and Harvard, AIDS research, Boston, MA, United States of America
Acute-phase response proteins are overexpressed in vaginal mucosa and plasma of HIV-resistant women upon viral challenge
Adam Burgener
Proteomics Group, National Lab for HIV Immunology, Public Health Agency of Canada, Winnipeg, Canada
Immune Complex – Fc Receptor Interactions Reduce Inflammatory Responses at the Genital Mucosa as a Correlate of SIV Vaccine-induced Protection
Liang Shang
University of Minnesota, Minneapolis, MN, United States of America
Synthetic DNA Vaccines - Enhancement of Adaptive EP Delivery
David B. Weiner
University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, United States of America
Immune correlates of a Functional Cure following therapeutic vaccination of SIV-Infected Rhesus Macaques
Deborah Fuller
University of Washington, Microbiology, Seattle, WA, United States of America
from AIDS Vaccine 2013 on 9 October 2013 10:30 AM-12:00 PM
Symposium 04: Viral Vaccine Vectors
Development of HIV Vaccines - a Vaccine Manufacturer's Perspective
Gerald Voss
GlaxoSmithkline Vaccines, Rixensart, Belgium
Sendai Virus Vector Vaccine
Tetsuro Matano
National Institute of Infectious Diseases, Tokyo, Japan
Reinventing the Nucleic Acid Vaccine
Andrew Geall
Novartis Vaccine and Diagnostics, Cambridge, MA, United States of America
Durable Antibody Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like Particles
Harriet Robinson
GeoVax, Inc., Smyrna, GA, United States of America
from AIDS Vaccine 2013 on 9 October 2013 10:30 AM-12:00 PM
Roundtable Discussion: Clinical Trial Follow-up and Retention
Retention in the Step Study
Susan Buchbinder
San Francisco Department of Public Health, San Francisco, CA, United States of America
Merck Vaccine: Step and Phambili Schema
Glenda Gray
Perinatal HIV Research Unit, Johannesburg, South Africa
Phase 2b Trial of the VRC's DNA/rAd5 Vaccine Regimen in Circumcised, Ad5 Neut Ab(-) Persons in the United States
Scott Hammer
Columbia University Medical Center, New York, NY, United States of America
Follow Up & Retention in Phase III Efficacy Trials in Thailand
Punnee Pitisuttithum
Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
Roundtable Discussion: Clinical Trial Follow-up and Retention
Sheena McCormack
MRC Clinical Trials Unit, London, United Kingdom
José María Miró
barnaclínic+, Grup Hospital Clinic, Barcelona, Spain
Susan Buchbinder
San Francisco Department of Public Health, San Francisco, CA, United States of America
Glenda Gray
Perinatal HIV Research Unit, Johannesburg, South Africa
Scott Hammer
Columbia University Medical Center, New York, NY, United States of America
Punnee Pitisuttithum
Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
from AIDS Vaccine 2013 on 9 October 2013 1:00 PM-2:30 PM
Symposium 05: New Targets from Acute Infection
Targeting the Female Reproductive Tract Epithelium to Prevent Transmission and Acute Systemic Infection: Lessons Learned in the SIV-NHP Model
Ashely Haase
University of Minnesota, Minneapolis, MN, United States of America
Host-Virus Interactions in HIV-1 Rapid Disease Progression
Javier Martinez-Picado
AIDS Research Institute IrsiCaixa,Autonomous University of Barcelona, Barcelona, Spain
Using an Autologous HIV Vaccine/Activator (Based on the Full Length Virus Genome and the Intrapatient Virus Population) to INCOMPELTE
Eric Arts
Case Western Reserve University (CWRU) School of Medicine, Cleveland, OH, United States of America
Modeling the Effects of Vaccination on Acute Phase CD8+ T Cell Immunodominance Patterns to HIV in Humanized Mice
Todd Allen
Ragon institute of MGH, MIT and Harvard, Cambridge, MA, United States of America
from AIDS Vaccine 2013 on 9 October 2013 1:00 PM-2:30 PM
Symposium 06: Humoral Immunity
A Pure Native Env Trimer Vaccine Elicits Potent Tier 2 Neutralization to a Quarternary, Glycan-Sensitive Epitope
James Binley
Torrey Pines Institute for Molecular Studies, San Diego, CA, United States of America
Structure of a soluble, cleaved HIV-1 Env trimer and its recognition by broadly neutralizing antibodies
Ian Wilson
The Scripps Research Institute, La Jolla, CA, United States of America
HIV Vaccine Design to Induce Broadly Neutralizing Antibodies
William Schief
IAVI Neutralizing Antibody Center and Department of Immunology and Microbial Science, Scripps Research Institute, La Jolla, CA, United States of America
Recombinant Env Interactions with the BCRs of Broadly Neutralizing Anti-HIV Antibodies
Leonidas Stamatatos
Seattle Biomedical Research Institute, Seattle, WA, United States of America
from AIDS Vaccine 2013 on 9 October 2013 1:00 PM-2:30 PM
Symposium 07: Therapeutic Vaccines & Viral Latency
Dendritic Cell-based Immunotherapy in HIV-infection: “A Bridge Over Troubled Water”
Jean-Pierre Routy
McGill University, Montreal, Canada
Viral Persistence Under ART and the Challenges of Eradicating Myeloid Reservoirs
Mario Stevenson
University of Miami Miller School of Medicine, Miami, FL, United States of America
Therapeutic Concepts for HIV Eradication
Romas Geleziunas
Gilead Sciences, Inc., Foster City, CA, United States of America
Immune Mechanisms and HIV Eradication
Michael Lederman
Case Western Reserve University, University Hospitals Case Medical Center, Cleveland, OH, United States of America
from AIDS Vaccine 2013 on 9 October 2013 3:00 PM-4:20 PM
Symposium 08: New Vaccine Concepts
Refocusing CTL and Antibody Responses with p24gag Conserved Elements Vaccines
James Mullins
University of Washington, Seattle, WA, United States of America
HIVACAT T- and B-cell Immunogen Design and Preclinical Testing
Christian Brander
IrsiCaixa Foundation, HIVACAT, ICREA, Barcelona, Spain, Barcelona, Spain
Protection against HIV: Vaccination to Block Inflammation
Joseph M. McCune
University of California at San Francisco, San Francisco, CA, United States of America
mRNA as a versatile vaccination tool
Joeri Aerts
Laboratory of Molecular and Cellular Therapy, Vrije Universiteit Brussels (VUB), Brussels Belgium
from AIDS Vaccine 2013 on 9 October 2013 3:00 PM-4:20 PM
Symposium 09: Mucosal Immunity
Visualizing Cellular Dynamics of HIV Infection In Vivo
Thomas Murooka
Massachusetts General Hospital, Boston, MA, United States of America
Dynamic Interplay between Virus and Host Occurring at the Female Reproductive Tract During Acute HIV Infection and Treatment
J. Victor Garcia-Martinez
University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America
Identification and Characterization of Specific IgG-mucin Interactions to Enhance Vaccine Function
Thomas Hope
Northwestern University, Chicago, IL, United States of America
Prime and Pull: A Vaccine Strategy for Viral Sexually Transmitted Infections
Haina Shin
Yale University School of Medicine, New Haven, CT, United States of America
from AIDS Vaccine 2013 on 9 October 2013 3:00 PM-4:20 PM
Plenary 03: Innovations in HIV Vaccine Discovery
Nanotechnology Approaches for Designing Novel HIV Vaccines
Maria Jose Alonso
University of Santiago de Compostela, Santiago de Compostela, Spain
Cutaneous Routes for HIV Vaccination Strategies
Behazine Combadiere
INSERM, UPMC, Paris, France
HIV Vaccine Development: A View from the Outside
Adrian Hill
Jenner Institute, University of Oxford, Oxford, United Kingdom (Great Britain)
from AIDS Vaccine 2013 on 10 October 2013 8:30 AM-10:00 AM
Plenary 04: Emerging Clinical Trial Data
The First Clinical Evaluation of Conserve-Region Vaccines in Humans
Tomas Hanke
University of Oxford, Oxford, United Kingdom (Great Britain)
The HIVIS and TaMoVac Studies, a North - South Collaboration
Muhammad Bakari
Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania, United Republic of
Looking Back to Move Forward: Understanding ALVAC/AIDSVAX Immune Responses
Merlin Robb
U.S. Military HIV Research Program (MHRP), Bethesda, MD, United States of America
Vaccine Induced Antibody Responses in HVTN 505, a Phase IIb HIV-1 Efficacy Trial
Georgia Tomaras
Duke University, Durham, NC, United States of America
An Update on the Phambili/HVTN 503 Study, a Phase IIB HIV Vaccine Efficacy Study Investigating MRK Ad5 HIV-1 Subtype B gag/pol/nef Vaccine
Glenda Gray
Perinatal HIV Research Unit, Johannesburg, South Africa
Meta-Analysis of Ad5-vector HIV Vaccine Trials to Assess the Vaccine Effect on HIV Acquisition
Peter Gilbert
Fred Hutchinson Cancer Research Center, Seattle, WA, United
from AIDS Vaccine 2013 on 10 October 2013 10:30 AM-1:00 PM
Closing Session
What Has 30 Years of HIV Vaccine Research Taught Us? Lessons from the past to inform the future
José Esparza
Bill and Melinda Gates Foundation, Seattle, WA, United States of America
AIDS Vaccine 2013 At-A-Glance
Christian Brander
IrsiCaixa Foundation, HIVACAT, ICREA, Barcelona, Spain, Barcelona, Spain
Bonaventura Clotet
IrsiCaixa Foundation, HIVACAT, Barcelona, Spain
José M. Gatell
Hospital Clínic-IDIBAPS, University of Barcelona, HIVACAT, Spain, Barcelona, Spain
AIDS Vaccine Research, Where We Are and Where We Are Going
Nina Russell
Bill and Melinda Gates Foundation, Global HIV Vaccine Enterprise, New York, NY, United States of America
HIV R4P Conference Announcement
Eric Hunter
Emory University, Atlanta, GA, United States of America
Robin Shattock
Imperial College London, London, United Kingdom (Great Britain)
from AIDS Vaccine 2013 on 10 October 2013 1:00 PM-1:50 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 sessions: 1 to 25 of 25